Home » Stocks » IONS

Ionis Pharmaceuticals, Inc. (IONS)

Stock Price: $38.03 USD 0.54 (1.44%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Market Cap 5.36B
Revenue (ttm) 707.50M
Net Income (ttm) -492.93M
Shares Out 140.77M
EPS (ttm) -3.59
PE Ratio n/a
Forward PE 90.91
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $38.03
Previous Close $37.49
Change ($) 0.54
Change (%) 1.44%
Day's Open 37.52
Day's Range 37.00 - 38.21
Day's Volume 949,248
52-Week Range 34.43 - 64.37

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

These biotech stocks could have great long-term potential.

Other stocks mentioned: EDIT, IGMS, XNCR, ZYME
2 days ago - The Motley Fool

CARLSBAD, Calif., July 21, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, August 4 th at 11:30 a.m.

4 days ago - PRNewsWire

Ionis (IONS) signs a deal with Bicycle Therapeutics to incorporate the latter's optimized Bicycle peptides into its LICA delivery platform.

Other stocks mentioned: BCYC
1 week ago - Zacks Investment Research

Bicycle Therapeutics plc (NASDAQ: BCYC) announced that Ionis Pharmaceuticals Inc (NASDAQ: IONS) has exercised its option and entered into an exclusive worldwide license and collaboration agreement to de...

Other stocks mentioned: BCYC
1 week ago - Benzinga

CARLSBAD, Calif., July 13, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that it has entered into an exclusive licensing agreement with Bicycle Therapeutics plc (NASDAQ...

Other stocks mentioned: BCYC
1 week ago - PRNewsWire

You can get a lot of bang for the buck with these picks.

Other stocks mentioned: PACB, SKLZ
1 week ago - The Motley Fool

CLPR, IONS, RAD, TFFP, and VNCE have been added to the Zacks Rank #5 (Strong Sell) List on July 8, 2021

Other stocks mentioned: CLPR, RAD, TFFP, VNCE
2 weeks ago - Zacks Investment Research

Recent trial disappointments scared off some investors.

Other stocks mentioned: VRTX
2 weeks ago - The Motley Fool

We believe that the stock price of Ionis Pharmaceuticals, a biotech company that specializes in discovering and developing RNA-targeted therapeutics, is undervalued at current levels of under $37. IONS ...

1 month ago - Forbes

Analysts view all three as rebound candidates.

Other stocks mentioned: QDEL, SMG
1 month ago - The Motley Fool

CARLSBAD, Calif., June 14, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that Executive Vice President and Chief Scientific Officer C.

1 month ago - PRNewsWire

CARLSBAD, Calif., June 10, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, today announced that multiple presentations highlighting advances in its...

1 month ago - PRNewsWire

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

CARLSBAD, Calif., June 2, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced changes to its board of directors.

1 month ago - PRNewsWire

A modest amount goes a long way when you invest in biotech stocks.

Other stocks mentioned: FATE, NVAX, VRTX
1 month ago - The Motley Fool

CARLSBAD, Calif., May 26, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present a company overview at the following virtual investor conferences: W...

1 month ago - PRNewsWire

With the trading day about halfway over, markets pushed higher into the weekend. The Nasdaq was the biggest winner on the day, with the index up over 1.3%.

Other stocks mentioned: ETSY, MNST, NOK, EPZM, FATE, NTLA
2 months ago - 24/7 Wall Street

Ionis (IONS) Q1 adjusted loss per share was wider than the year-ago figure. The company maintains its guidance for 2021.

2 months ago - Zacks Investment Research

CARLSBAD, Calif., May 5, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2021 virtual Annual Meeting of Stockholders followed by a genera...

2 months ago - PRNewsWire

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of -33.33% and -16.06%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

CARLSBAD, Calif., May 5, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the first quarter of 2021 and recent business highlights.

2 months ago - PRNewsWire

Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

CARLSBAD, Calif., April 21, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, May 5 th at 11:30 a.m.

3 months ago - PRNewsWire

CARLSBAD, Calif., April 20, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced it has initiated a pivotal clinical study of ION373 in patients with Alexander disease, a rare...

3 months ago - PRNewsWire

We believe that Ionis Pharmaceuticals stock, a biotech company that specializes in discovering and developing RNA-targeted therapeutics, is a good buying opportunity at the present time. IONS stock trad...

3 months ago - Forbes

CARLSBAD, Calif., April 8, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today the pricing of $550.0 million aggregate principal amount of 0% Convertible Senior Notes due 202...

3 months ago - PRNewsWire

Ionis Pharmaceuticals Inc (NASDAQ: IONS) said it expanded its distribution agreement with Swedish Orphan Biovitrum AB (“Sobi”) for Tegsedi in North America. Tegsedi is indicated for polyneuropathy (a co...

Other stocks mentioned: AKCA
3 months ago - Benzinga

CARLSBAD, Calif., April 6, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it intends to offer, subject to market conditions and other factors, $500.0 million aggreg...

3 months ago - PRNewsWire

NEW YORK, April 6, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are advised ...

3 months ago - PRNewsWire

CARLSBAD, Calif., April 5, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the initiation of a Phase 3 clinical trial of ION363 in patients with amyotrophic lateral scler...

3 months ago - PRNewsWire

NEW YORK, March 30, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS).  Such investors are advise...

3 months ago - PRNewsWire

Ionis Pharmaceuticals Inc (NASDAQ: IONS) has announced data from a Phase 2 study evaluating IONIS-PKK-LRx in patients with hereditary angioedema (HAE). The study met its primary and secondary endpoints,...

3 months ago - Benzinga

CARLSBAD, Calif., March 29, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that data from a Phase 2 clinical study of IONIS-PKK-LRx met its primary and secondary endpoin...

3 months ago - PRNewsWire

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?

3 months ago - Zacks Investment Research

CARLSBAD, Calif., March 26, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, today announced that management will participate in virtual fireside...

3 months ago - PRNewsWire

Cathie Wood's Ark Invest continues to add more shares to its holdings with it picking out a few companies worth noting on Wednesday. The post DDD, AONE, RAVN, ION: 4 Stocks That Cathie Wood's ARK Funds ...

Other stocks mentioned: AONE, DDD, RAVN
4 months ago - InvestorPlace

The biotech's partner is stopping a late-stage clinical trial for a Huntington's disease treatment.

4 months ago - The Motley Fool

Ionis (IONS) stock sinks as partner Roche stops dosing in a late-stage study on tominersen in Huntington's disease.

Other stocks mentioned: RHHBY
4 months ago - Zacks Investment Research

Roche Holdings AG (OTCMKTS: RHHBY) has halted dosing for its Phase 3 study of tominersen, an antisense drug targeting the huntingtin protein and a mutant variant. Roche is calling off the study after an...

4 months ago - Benzinga

Every night, Cathie Wood's Ark Investment Management sends out an email listing the stocks that were bought or sold by the firm's ETFs that day. In recent months, the emails have been known to cause cer...

Other stocks mentioned: DDD, DE
4 months ago - Benzinga

CARLSBAD, Calif., March 22, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced its partner, Roche, has decided to discontinue dosing in the Phase III GENERATION HD1 study of tomin...

4 months ago - PRNewsWire

In December 2020 we talked about how Ionis Pharmaceuticals stock seems to be oversold, and since then the stock has seen a 15% rise to levels of $54 currently. However, the company's lackluster Q4 resul...

4 months ago - Forbes

CARLSBAD, Calif., March 1, 2021 /PRNewswire/ -- Ionis Pharmaceuticals (NASDAQ: IONS) today announced that the company has launched a new grant program that provides funding to U.S.-based researchers who...

4 months ago - PRNewsWire

Ionis (IONS) Q4 adjusted earnings decline year over year. The company issues guidance for 2021.

4 months ago - Zacks Investment Research

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of -1116.67% and 9.05%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Shares of Ionis Pharmaceuticals (NASDAQ:IONS) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share fell 39.10% over the past year to $0.81, which beat the esti...

5 months ago - Benzinga

CARLSBAD, Calif., Feb. 24, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the fourth quarter of 2020 and recent business highlights. "Last year,...

5 months ago - PRNewsWire

CARLSBAD, Calif., Feb. 19, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, today announced that management will participate in a virtual firesid...

5 months ago - PRNewsWire

Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

CARLSBAD, Calif., Feb. 11, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, February 24th at 9:00 a.m. Eastern Time to discu...

5 months ago - PRNewsWire

About IONS

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclero... [Read more...]

Industry
Biotechnology
IPO Date
May 17, 1991
CEO
Brett Monia
Employees
757
Stock Exchange
NASDAQ
Ticker Symbol
IONS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 23 analysts, the average rating for IONS stock is "Buy." The 12-month stock price forecast is 57.83, which is an increase of 52.06% from the latest price.

Price Target
$57.83
(52.06% upside)
Analyst Consensus: Buy